Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
AssigneeJanssen Pharmaceutica NV
InventorPeter Marie Z. DE PORRE
Life of this patent
Estimating the term…
Abstract
Described herein methods of treating urothelial carcinoma with an approved drug product containing a fibroblast growth factor receptor (FGFR) inhibitor. Also described herein are methods of selling or offering for sale an approved drug product containing a fibroblast growth factor receptor (FGFR) inhibitor.
Claims42
A method of treating urothelial carcinoma comprising administering erdafitinib to a patient with a urothelial carcinoma wherein erdafitinib is co-administered with a P-glycoprotein (P-gp) substrate and
- administration of erdafitinib is separated by at least 6 hours before or after administration of the P-gp substrate, wherein the P-gp substrate has a narrow therapeutic index.
A method of treating urothelial carcinoma comprising administering erdafitinib to a patient with a urothelial carcinoma wherein erdafitinib is co-administered with a moderate CYP2C9 or CYP3A4 inducer.
23-47. (canceled)
Dependencies are inferred from the claim text.